UPCC 21823 Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease (PTBB)

Investigating Prostate Cancer in Individuals with Genetic Risk

Enrolling By Invitation
18 years or above
Male
Phase N/A
200 participants needed
1 Location

Brief description of study

Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. The investigators have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation.

The Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples. Our primary goal is to investigate prostate cancer development and treatment response in carriers of germline DNA repair mutations, as compared to non-carrier controls.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostate Cancer, Genetic Predisposition
  • Age: 18 years or above
  • Gender: Male

Inclusion Criteria:

Carriers (Group 1):

  1. Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene.
  2. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer

Controls (Group 2):

  1. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer

Exclusion Criteria:

  • N/A

The purpose of this study is to investigate prostate cancer in individuals who have a genetic risk for the disease. Prostate cancer is a common cancer in men, especially those with inherited genetic changes in certain genes like BRCA1, BRCA2, ATM, TP53, and HOXB13. These genetic changes can increase the risk of developing prostate cancer. This study focuses on collecting prostate tissue samples and DNA from men with these genetic changes to understand prostate cancer development and treatment responses better.

Participants will undergo procedures like prostate biopsies or prostatectomies to provide tissue samples for the study. The study will compare these samples with those from men without these genetic changes to see how prostate cancer develops differently in these two groups. The collected samples will be stored in a biobank for future research.

  • Who can participate: Men with a confirmed genetic change in a known prostate cancer risk gene undergoing prostate biopsies or prostatectomy are eligible. Men without these genetic changes but undergoing similar procedures can participate as controls.
  • Study details: Participants will provide prostate tissue samples through biopsies or prostatectomies. These samples will be used to study prostate cancer development and responses to treatment.
Updated on 28 Jul 2026. Study ID: 23-1233
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator